У нас вы можете посмотреть бесплатно A new IPF treatment has been approved или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
BREAKING NEWS for the pulmonary fibrosis community! For the first time in more than a decade, a new treatment is now approved for IPF. Today, the U.S. Food and Drug Administration approved Boehringer Ingelheim’s nerandomilast (Jascayd) for the treatment of IPF. Nerandomilast, an oral phosphodiesterase 4B (PDE4B) inhibitor, demonstrated statistically significant efficacy in slowing the rate of lung function decline among participants in the Phase III FIBRONEER-IPF clinical trial. Data from the positive phase 3 FIBRONEER-ILD trial of nerandomilast in progressive pulmonary fibrosis is expected to be reviewed by the FDA in the coming months. This approval represents an important milestone for patients, caregivers, and clinicians, offering new possibilities in the care and management of pulmonary fibrosis, and helping to close the gap on unmet needs for patients living with IPF. Yet, the burden of this disease remains profound, and the need for additional effective treatments continues. The Pulmonary Fibrosis Foundation remains steadfast in its commitment to advancing research, expanding education, and providing essential support to patients and their families. Together with our partners across the scientific and patient communities, we will continue working toward improved outcomes and, ultimately, a cure for pulmonary fibrosis.